Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenxia Zhao

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
International Journal of Nanomedicine|December 3, 2020
Endocytosis and Organelle Targeting of Nanomedicines in Cancer TherapyXiaowei Wang, Yuhan Qiu, Mengyan Wang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 20, 2012
MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit deltaFang Cui, Xiuli Li, Xiangyu Zhu, et al.
Pharmacoepidemiology and Drug Safety|June 10, 2022
Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System databaseSiyuan Gao, Zhichao He, Jianhong Zhu, et al.
International Immunopharmacology|August 18, 2022
Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing dataJianhong Zhu, Muhua Luo, Dan Liang, et al.
Acta Diabetologica|December 28, 2022
SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessmentZhichao He, Kakei Lam, Wenxia Zhao, et al.
The Lancet. Diabetes & Endocrinology|February 2, 2020
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence mapJianhong Zhu, Xiaoxia Yu, Yayuan Zheng, et al.
Toxics|January 28, 2026
Direct Valorization of Biogas Residue: A Comparative Study on Facile Chemical Modifications for Superior Adsorption of Anionic DyesXin Luo, Wenxia Zhao, Lin Fu, et al.
Chemico-Biological Interactions|September 22, 2023
Icariin inhibits hypertrophy by regulation of GPER1 and CaMKII/HDAC4/MEF2C signaling crosstalk in ovariectomized miceWenxia Zhao, Xiaoli Shan, Xueqin Li, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 14, 2020
Transcriptional co-activators YAP/TAZ: Potential therapeutic targets for metastatic breast cancerWenxia Zhao, Mengyan Wang, Meilian Cai, et al.
Expert Opinion on Drug Safety|March 10, 2017
Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumabJianhong Zhu, Junyan Wu, Guocheng Li, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
International Journal of Nanomedicine|December 3, 2020
Endocytosis and Organelle Targeting of Nanomedicines in Cancer TherapyXiaowei Wang, Yuhan Qiu, Mengyan Wang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 20, 2012
MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit deltaFang Cui, Xiuli Li, Xiangyu Zhu, et al.
Pharmacoepidemiology and Drug Safety|June 10, 2022
Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System databaseSiyuan Gao, Zhichao He, Jianhong Zhu, et al.
International Immunopharmacology|August 18, 2022
Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing dataJianhong Zhu, Muhua Luo, Dan Liang, et al.
Acta Diabetologica|December 28, 2022
SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessmentZhichao He, Kakei Lam, Wenxia Zhao, et al.
The Lancet. Diabetes & Endocrinology|February 2, 2020
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence mapJianhong Zhu, Xiaoxia Yu, Yayuan Zheng, et al.
Toxics|January 28, 2026
Direct Valorization of Biogas Residue: A Comparative Study on Facile Chemical Modifications for Superior Adsorption of Anionic DyesXin Luo, Wenxia Zhao, Lin Fu, et al.
Chemico-Biological Interactions|September 22, 2023
Icariin inhibits hypertrophy by regulation of GPER1 and CaMKII/HDAC4/MEF2C signaling crosstalk in ovariectomized miceWenxia Zhao, Xiaoli Shan, Xueqin Li, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 14, 2020
Transcriptional co-activators YAP/TAZ: Potential therapeutic targets for metastatic breast cancerWenxia Zhao, Mengyan Wang, Meilian Cai, et al.
Expert Opinion on Drug Safety|March 10, 2017
Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumabJianhong Zhu, Junyan Wu, Guocheng Li, et al.
Pageof 11